The neurotoxin 1-methyl-4-phenylpyridinium is sequestered within neurons that contain the vesicular monoamine transporter

Neuroscience

Volumn 84, Issue 4, 1998, Pages 1177-1185

  Speciale, S G ^a   Liang, C L ^a   Sonsalla, P K ^b   Edwards, R H ^c   German, D C ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Monoaminergic neurons; Mouse; MPTP; Parkinson's disease

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; CARRIER PROTEIN; NEUROTOXIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN REGION; DOPAMINERGIC NERVE CELL; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; LOCUS CERULEUS; MALE; MONOAMINERGIC SYSTEM; MOUSE; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PROTEIN DETERMINATION; STRIA TERMINALIS; THALAMUS MIDLINE NUCLEUS;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; AUTORADIOGRAPHY; BRAIN; DOPAMINE AGENTS; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, INBRED C57BL; NEURONS; NEUROPEPTIDES; NEUROTOXINS; PARKINSON DISEASE, SECONDARY; VESICULAR BIOGENIC AMINE TRANSPORT PROTEINS; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 0031959882     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(97)00570-8     Document Type: Article

References (48)

1. 1. Burns R. S., Chiueh C. C., Markey S. P., Ebert M. H., Jacobowitz D. M. and Kopin I. J. (1983) A primate model of Parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. natn. Acad. Sci. U.S.A. 80, 4546-4550.
2. 2. Chan P., DeLanney L. E., Irwin I., Langston J. W. and Di Monte D. (1991) Rapid ATP loss caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse brain. J. Neurochem. 57, 348-351.
3. 3. Chiba K., Trevor A. and Castagnoli N. (1984) Metabolism of the neurotoxic amine, MPTP, by brain monoamine oxidase. Biochem. biophys. Res. Commun. 120, 574-578.
4. 4. Daniels A. J. and Reinhard J. F. (1988) Energy-driven uptake of the neurotoxin 1-methyl-4-phenylpyridinium into chromaffin granules via the catecholamine transporter. J. biol. Chem. 263, 5034-5036.
5. 125I]iodoketanserin. Neuroscience 33, 341-349.
6. + in mouse striatal membranes. Brain Res. 571, 354-357.
7. + uptake into synaptic dopamine vesicles possible involvement in MPTP neurotoxicity. Br. J. Pharmac. 109, 411-414.
8. 8. German D. C., Dubach M., Askari S., Speciale S. G. and Bowden D. M. (1988) 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced Parkinsonism syndrome in Macaca fascicularis: which midbrain dopaminergic neurons are lost? Neuroscience 24, 161-174.
9. 28k-containing cells. Ann. N. Y. Acad. Sci. 648, 42-62.
10. 10. German D. C., Nelson E. L., Liang C.-L., Speciale S. G., Sinton C. M. and Sonsalla P. K. (1996) The neurotoxin MPTP causes degeneration of specific nucleus A8, A9 and A10 dopaminergic neurons in the mouse. Neurodegeneration 5, 299-312.
11. 11. Gessner W., Brossi A., Shen R.-S., Fritz R. R. and Abell C. W. (1984) Conversion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its 5-methyl analog into pyridinium salts. Helv. chim. Acta 67, 2037-2042.
12. 12. Giovanni A., Sieber B.-A., Heikkila R. E. and Sonsalla P. K. (1994) Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 1: Systemic administration. J. Pharmac. exp. Ther. 270, 1000-1007.
13. 13. Giovanni A., Sonsalla P. K. and Heikkila R. E. (1994) Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 2: Central administration of 1-methyl-4-phenylpyridinium. J. Pharmac. exp. Ther. 270, 1008-1014.
14. 14. Heikkila R. E., Hess A. and Duvoisin R. C. (1984) Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice Science 224, 1451-1453.
15. 15. Heikkila R. E., Manzino L., Cabbat F. S. and Duvoisin R. C. (1984) Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311, 467-469.
16. + within the monoaminergic systems of the primate brain following MPTP administration: an in vivo autoradiographic study. Neuroscience 40, 133-158.
17. + in the nigrostriatal and mesolimbic dopaminergic pathways. Neurosci. Lett. 196, 93-96.
18. + in the mouse brain. Neurosci. Lett. 101, 83-88.
19. + in the substantia nigra: a key to neurotoxicity? Life Sci. 36, 207-212.
20. 20. Javitch J. A., D'Amato R. J., Strittmatter S. M. and Snyder S. N. (1985) Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenyl-pyndinium by dopamine neurons explains selective toxicity. Proc. natn. Acad. Sci. U.S.A. 82, 2173-2177.
21. 21. Johannessen J. N., Chiueh C. C., Herkenham M. A., Markey S. P., Burns R. S., Adams J. D. and Schuller H. M. (1986) Relationship of the in vivo metabolism of MPTP to toxicity. In MPTP: A Neurotoxin Producing a Parkinsonian Syndrome (eds Markey S. P., Castagnoli N., Trevor A. J. and Kopin I. J.), pp 173-189. Academic, New York.
22. 22. Langston J. W., Ballard P., Tetrud J. W. and Irwin I. J. (1983) Chronic Parkinsonism in humans due to a product of meperidine analog synthesis. Science 219, 979-980.
23. 23. Lavoie B. and Parent A. (1991) Dopaminergic neurons expressing calbindin in normal and Parkinsonian monkeys. NeuroReport 2, 601-604.
24. +. J. neural Transm. 93, 75-82.
25. 25. Levitt P., Pintar J. E. and Breakefield X. O. (1982) Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons. Proc. natn. Acad. Sci. U.S.A. 79, 6385-6389.
26. 26. Liang C.-L., Sinton C. M. and German D. C. (1996) Midbrain dopaminergic neurons in the mouse: colocalization with calbindin and calretinin. Neuroscience 75, 523-533.
27. 28k are selectively invulnerable to MPTP-induced neurodegeneration. Neurodegeneration 5, 313-318.
28. + toxicity encodes a vesicular amine transporter. Cell 70, 539-551.
29. 29. Lyden A., Bondesson U., Larsson B. S., Lindquist N. G. and Olsson L.-I. (1985) Autoradiography of 1-methyl-4-phenyl-1,2,3.6-tetrahydropyridine: uptake in the monoaminergic pathways and in melanin containing tissues. Acta pharmac. toxicol. 59, 130-135.
30. 30. Markey S. P., Johannessen J. N., Chiueh C. C., Burns R. S. and Herkenham M. A. (1984) Intraneuronal generation of a pyridinium metabolite may cause drug-induced Parkinsonism. Nature 311, 464-467.
31. 31. Nelson E. L., Liang C.-L., Sinton C. M. and German D. C. (1996) Midbrain dopaminergic neurons in the mouse: computer-assisted mapping. J. comp. Neurol. 369, 361-371.
32. +, a metabolite of the neurotoxin MPTP. Life Sci. 36, 2503-2508.
33. 33. Nwanze E., Souverbie F., Jonsson G. and Sundstrom E. (1995) Regional biotransformation of MPTP in the CNS of rodents and its relation to neurotoxicity. Neurotoxicology 16, 469-478.
34. 34. Peter D., Liu Y., Sternini C., de Giorgio R., Brecha N. and Edwards R. H. (1995) Differential expression of two vesicular monoamine transporters. J. Neurosci. 15, 6179-6188.
35. +. Neurosci. Lett. 75, 323-328.
36. 36. Reinhard J. F., Daniels A. J. and Viveros O. H. (1988) Potentiation by reserpine and tetrabenazine of brain catecholamine depletions by MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) in the mouse: evidence for subcellular sequestration as a basis for cellular resistance to the toxicant. Neurosci. Lett. 90, 349-353.
37. 37. Reinhard J. F., Diliberto E. J., Viveros O. H. and Daniels A. J. (1987) Subcellular compartmentalization of 1-methyl-4-phenylpyridinium with catecholamines in adrenal medullary chromaffin vesicles may explain the lack of toxicity to adrenal chromaffin cells. Proc. natn. Acad Sci. U.S.A. 84, 8160-8164.
38. 38. Russo S. M., Daniels A. J., Viveros O. H. and Reinhard J. R. Jr. (1994) Differences in the reserpine-sensitive storage in vivo of 1-methyl-4-phenylpyridinium in rats and mice may explain differences in catecholamine toxicity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurotoxicol. Teratol. 16, 277-281.
39. 39. Schwartz J.-C., Arrang J.-M., Garbarg M., Pollard H. and Ruat M. (1991) Histaminergic transmission in the mammalian brain. Physiol. Rev. 71, 1-51.
40. 40. Shore P. A. (1962) Release of serotonin and catecholamines by drugs. Pharmac. Rev. 14, 531-550.
41. 41. Sonsalla P. K. and Heikkila R. E. (1986) The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice. Eur. J. Pharmac. 129, 339-345.
42. 42. Staal R. G. W., Hogan K. A., Manzino L. and Sonsalla P. K. (1997) Greater levels of vesicular monoamine transporter (VMAT2) in rat vs mouse striatum may help explain MPTP resistance in rats. The Pharmacologist 39, 89.
43. 43. Sundstrom E., Stromberg I., Tsutsumi T., Olson L. and Jonsson G. (1987) Studies on the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57BL/6 mice. Comparison with three other strains of mice. Brain Res. 405, 26-38.
44. 44. Ungerstedt U. (1971) Stereotaxic mapping of the monoamine pathways in the rat brain. Acta physiol. scand. 367 Suppl., 1-48.
45. 45. Vaccari A. and Saba P. L. (1995) The tyramine-labeled vesicular transporter for dopamine: a putative target of pesticides and neurotoxins. Eur. J. Pharmac. 292, 309-314.
46. 3H]Methoxytetrabenazine: a high specific activity ligand for estimating monoaminergic neuronal integrity. Neuroscience 68, 955-962.
47. 47. Walters A., Jackson-Lewis V., Sadik A. and Fahn S. (1987) Failure to produce chronic Parkinsonism with MPTP in rats. Biogenic Amines 1, 297-302.
48. + is accumulated in the nigrostriatal dopaminergic terminals but it is not neurotoxic: a model of natural resistance to MPTP toxicity. Expl Neurol. 127, 54-61.